ARTICLE | Product Development
J&J adds to emerging patchwork of COVID variant data, positions single-dose vaccine as bulwark against severe disease
J&J plans to seek EUA in days, on track with manufacturing goals
January 30, 2021 2:55 AM UTC
The second company to share vaccine efficacy data in the age of escape variants, J&J argues its candidate cannot be compared to those that read out in November, and points to the public health benefit of the single dose vaccine’s impact on severe disease.
Phase III data from Johnson & Johnson (NYSE:JNJ), announced Friday, comes a day after Novavax Inc. (NASDAQ:NVAX) presented the first glimpse of how the SARS-CoV-2 variants that have become dominant in the U.K. and South Africa fare against vaccines aimed at the virus’ spike protein. ...